Southern Company SO 25Year Dividend Growth Streak Extension Reinforces Income Investment Thesis Amid Capital Expenditure Execution Risks Summit Therapeutics SMMT Stock Is It the Right Time to Invest Q4 2025 Below Expectations Lucid Group LCID Valuation Assessment Weighing Macro Tailwinds Strategic Backing and Cash Burn Risks at 725 Per Share